Pandemic Darlings The pandemic economy, in original documents
Home Profiles Emergent BioSolutions

Profiles · Companies and entities

ProfileCompany or group

Emergent BioSolutions

Vendor or contractor

Type
Company or group
Role
Vendor or contractor
Updated
  • Type: Publicly traded contract development and manufacturing organization (CDMO) and biodefense company; Operation Warp Speed vaccine-manufacturing contractor.
  • Legal entity: Emergent BioSolutions Inc. (NYSE: EBS).
  • Founded: 1998 (as BioPort; renamed Emergent BioSolutions in 2004). Founder: Fuad El-Hibri (d. April 2022).
  • HQ: Gaithersburg, Maryland. Pandemic vaccine work centered on its Baltimore Bayview facility (drug substance) and Baltimore Camden and Rockville facilities (drug product).
  • Key people: Robert G. Kramer Sr. (president and CEO during the Bayview failures; later defendant in a 2026 New York insider-trading suit); Fuad El-Hibri (founder, executive chairman).
  • Role: Under Operation Warp Speed, Emergent's Bayview plant was designated the domestic manufacturing site for the drug substance of the Johnson & Johnson (Janssen) and AstraZeneca COVID-19 vaccines. It held a BARDA task order to reserve and build that capacity, plus separate CDMO contracts with J&J and AstraZeneca.

Role in pandemic relief

  • Reader shorthand: the Warp Speed manufacturer whose Baltimore plant ruined hundreds of millions of vaccine doses.
  • What Emergent did in the pandemic: committed and built cGMP manufacturing capacity for COVID-19 vaccine drug substance under a BARDA task order, and manufactured (or attempted to manufacture) J&J and AstraZeneca vaccine substance at Bayview.
  • Who Emergent's customers were: the federal government (BARDA/ASPR at HHS) funded the capacity build; Johnson & Johnson and AstraZeneca were the private CDMO customers whose vaccine substance Bayview produced.
  • Where responsibility sat: Emergent owned and ran Bayview; a congressional investigation found its own executives concealed quality failures from the FDA. The federal government funded the capacity and later terminated the contract "for convenience."

Before the pandemic

Emergent was already a U.S. biodefense contractor, known for anthrax vaccine and other medical-countermeasure work, with more than two decades of government contracting behind it. In 2012, a BARDA contract designated the Baltimore Bayview facility a Center for Innovation in Advanced Development and Manufacturing (CIADM), a public-private partnership meant to hold pandemic-preparedness manufacturing capacity "in a state of readiness." That standing arrangement is what Operation Warp Speed later activated.

Pandemic role (2020–2022)

The Warp Speed money (Emergent's account). On June 1, 2020, Emergent announced it had been issued a task order under its existing BARDA contract to join Operation Warp Speed, valued at approximately $628 million running through 2021: about $542.7 million to commit manufacturing capacity (drug substance at Bayview; drug product at Camden and Rockville) and about $85.5 million to expand fill/finish capacity. CEO Robert G. Kramer Sr. called it a "landmark" partnership. Emergent separately signed CDMO agreements with its two vaccine customers: a five-year drug-substance agreement with Johnson & Johnson (Janssen), announced July 6, 2020, with the first two years valued at about $480 million; and a U.S. manufacturing-partner agreement with AstraZeneca, announced June 11, 2020, at about $87 million initially.

What happened at Bayview. In March 2021, a cross-contamination event between the J&J and AstraZeneca production lines at Bayview ruined a batch of vaccine. The FDA ordered a manufacturing halt of roughly three months (April–August 2021). AstraZeneca's vaccine was never authorized in the United States, and its Bayview production was wound down.

The House report, the New York suit and the shareholder settlement

The House committees' report. On May 10, 2022, the House Committee on Oversight and Reform (Chairwoman Carolyn B. Maloney) and the Select Subcommittee on the Coronavirus Crisis (Chairman James E. Clyburn) released the final staff report of a year-long joint investigation, The Coronavirus Vaccine Manufacturing Failures of Emergent BioSolutions. Its central findings:

  • Nearly 400 million doses of coronavirus vaccine were destroyed because of Emergent's failure to meet and maintain quality standards, significantly more than previously known, including doses destroyed after the FDA-ordered halt. (The report's dose-destruction ledger describes roughly 240 million doses destroyed in late 2020–early 2021, about 195 million of them J&J and about 45.6 million AstraZeneca, with further tens of millions discarded after production resumed.)
  • Concealment from the FDA. Immediately before a February 2021 FDA site visit, Emergent employees removed quality-assurance "hold tags" from J&J vaccine batches "to avoid drawing attention" from inspectors, per an email obtained by the committees.
  • Ignored internal warnings. The report quoted an EVP of Manufacturing who had warned senior executives "for a few years" that quality systems were deficient ("room to improve is a huge understatement"); a Senior Director of Quality who wrote "Our risk is high!" and "we lack commercial GMP compliance maturity"; and an outside consultant who wrote in November 2020, "I am stating very loudly that this work is NON-CGMP compliant. And a direct regulatory risk."
  • Untrained staff. The report found "most temporary employees [have] little or no pharmaceutical experience," and that AstraZeneca concluded "poor cleaning was part of the root cause" of the contamination.
  • The money trail. HHS said Emergent received $330 million in taxpayer dollars before the Biden administration terminated the contract in November 2021. The termination was made "for the government's convenience," not for default, and HHS said it "saved taxpayers $320 million" remaining on the contract. Per the report, the Trump administration had earlier added $30 million to the contract, and senior executives received millions in raises and bonuses even as doses were destroyed.

The investigation had begun in April 2021, with a preliminary report and a May 19, 2021 hearing (at which Kramer and El-Hibri testified) and a September 2021 staff site visit to Bayview. All of these findings are the committees'.

The New York insider-trading suit. On January 15, 2026, New York Attorney General Letitia James sued former CEO Robert G. Kramer for insider trading under the Martin Act, and announced a settlement with Emergent (a $900,000 penalty for approving Kramer's trading plan). The OAG's complaint alleges that Emergent's summer-2020 AstraZeneca contracts (which the OAG values at a combined $261 million, a different scope from the House report's $174 million figure) sent Emergent stock up 43.6%. It alleges that Kramer then learned of the vaccine contamination internally in October 2020, put a Rule 10b5-1 trading plan in motion, and later sold shares for more than $10.1 million ahead of the public disclosure. The allegations against Kramer are unproven; Emergent resolved its part through an Assurance of Discontinuance, which the release does not describe as an admission. (Senator Elizabeth Warren had earlier, in 2021, called on the SEC to investigate Kramer's stock sales.)

Related shareholder litigation. A shareholder securities class action alleging false statements about Bayview's capabilities over a March 2020–November 2021 class period settled for $40 million, with final court approval in late February 2025 — a negotiated settlement, not a finding of liability.

Reconciling the numbers

Several contract figures differ by source and scope. The J&J drug-substance deal appears as ~$480 million (Emergent's July 2020 release, first two years) and as $482 million (House report, full contract), the same deal. The AstraZeneca work appears as ~$87 million (Emergent's June 2020 initial-agreement release), $174 million (House report, with later commercial-phase expansion), and a combined $261 million (NY OAG, summer-2020 contracts, different dates/scope). The BARDA task order is Emergent's headline federal figure at ~$628 million; the separate $330 million paid / $320 million saved figures come from HHS via the House committees.

  • Robert G. Kramer — Emergent CEO during the Bayview failures; defendant in the 2026 NY insider-trading suit.
  • James E. Clyburn — chaired the Select Subcommittee that co-authored the Emergent report.
  • Carolyn B. Maloney — chaired the Oversight Committee that co-authored the Emergent report.
  • Johnson & Johnson (Janssen) — the CDMO customer whose vaccine substance Bayview manufactured and whose roughly 195 million doses were destroyed in the plant's quality failures.

Sources

Primary and oversight documents

Company statements

Notes

  1. House Oversight / Select Subcommittee joint staff report, May 10, 2022, and its release. Source for the ~400 million destroyed doses, the dose-destruction ledger, the "hold tags" concealment, the internal-warning quotes, the $330M-paid / $320M-saved money trail, and the November 2021 "for convenience" termination. ↩
  2. New York OAG, Jan. 15, 2026. Allegations against Kramer are the OAG's and unproven; Emergent settled via Assurance of Discontinuance ($900,000 penalty) without a stated admission. The $261M AstraZeneca figure is the OAG's, a different scope from the House report's $174M. ↩
  3. Emergent BioSolutions press releases (June–July 2020) via GlobeNewswire. The $628M BARDA task order, $542.7M/$85.5M split, ~$480M J&J, and ~$87M AstraZeneca figures are Emergent's own. ↩
Back to top